Prolonged deficiency of protein C following hematopoietic stem cell transplantation

Bruce Geoffrey Gordon, W. Haire, E. Ruby, L. Stephens, G. Kotulak, A. Kessinger

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Deficiencies in circulating anticoagulant protein C (PC) occur in patients undergoing hematopoietic stem cell transplantation. These deficiencies may predispose to thrombotic and other complications, and may contribute to the morbidity of transplantation. In most patients, PC reaches a nadir 14 days after the preparative regimen and then begins to increase toward normal. However, low PC has been seen months after transplantation. Neither the frequency of, nor risk factors for, this prolonged deficiency are known. We examined 71 adults undergoing stem cell transplantation and found low PC antigen and activity in 21% and 20% of patients, respectively. Low PC at day 100 correlated strongly with low PC pre-chemotherapy (PC antigen, r = 0.69, P < 0.001; PC activity, r = 0.59, P < 0.001). The incidence of deficiency of PC at day 100 was lower in patients undergoing peripheral stem cell transplantation compared with patients undergoing autologous BMT (12.5% vs 35%; P = 0.05), although several significant confounding variables exist. We conclude that deficiencies in protein C persist at least 100 days after stem cell transplantation in nearly one quarter of patients undergoing this procedure. Therefore, patients undergoing stem cell transplantation may be at prolonged risk of thrombotic and other complications. Further studies to determine the risk of prolonged deficiency based on stem cell source need to be performed.

Original languageEnglish (US)
Pages (from-to)415-419
Number of pages5
JournalBone marrow transplantation
Volume17
Issue number3
StatePublished - Mar 1 1996

Fingerprint

Protein C Deficiency
Hematopoietic Stem Cell Transplantation
Protein C
Stem Cell Transplantation
Transplantation
Antigens
Peripheral Blood Stem Cell Transplantation
Adult Stem Cells
Confounding Factors (Epidemiology)
Stem Cells
Morbidity
Drug Therapy

Keywords

  • Hematopoietic growth factors
  • Hypercoagulable state
  • Protein C

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Gordon, B. G., Haire, W., Ruby, E., Stephens, L., Kotulak, G., & Kessinger, A. (1996). Prolonged deficiency of protein C following hematopoietic stem cell transplantation. Bone marrow transplantation, 17(3), 415-419.

Prolonged deficiency of protein C following hematopoietic stem cell transplantation. / Gordon, Bruce Geoffrey; Haire, W.; Ruby, E.; Stephens, L.; Kotulak, G.; Kessinger, A.

In: Bone marrow transplantation, Vol. 17, No. 3, 01.03.1996, p. 415-419.

Research output: Contribution to journalArticle

Gordon, BG, Haire, W, Ruby, E, Stephens, L, Kotulak, G & Kessinger, A 1996, 'Prolonged deficiency of protein C following hematopoietic stem cell transplantation', Bone marrow transplantation, vol. 17, no. 3, pp. 415-419.
Gordon BG, Haire W, Ruby E, Stephens L, Kotulak G, Kessinger A. Prolonged deficiency of protein C following hematopoietic stem cell transplantation. Bone marrow transplantation. 1996 Mar 1;17(3):415-419.
Gordon, Bruce Geoffrey ; Haire, W. ; Ruby, E. ; Stephens, L. ; Kotulak, G. ; Kessinger, A. / Prolonged deficiency of protein C following hematopoietic stem cell transplantation. In: Bone marrow transplantation. 1996 ; Vol. 17, No. 3. pp. 415-419.
@article{cf8ecf732abf4af7b56230674f477231,
title = "Prolonged deficiency of protein C following hematopoietic stem cell transplantation",
abstract = "Deficiencies in circulating anticoagulant protein C (PC) occur in patients undergoing hematopoietic stem cell transplantation. These deficiencies may predispose to thrombotic and other complications, and may contribute to the morbidity of transplantation. In most patients, PC reaches a nadir 14 days after the preparative regimen and then begins to increase toward normal. However, low PC has been seen months after transplantation. Neither the frequency of, nor risk factors for, this prolonged deficiency are known. We examined 71 adults undergoing stem cell transplantation and found low PC antigen and activity in 21{\%} and 20{\%} of patients, respectively. Low PC at day 100 correlated strongly with low PC pre-chemotherapy (PC antigen, r = 0.69, P < 0.001; PC activity, r = 0.59, P < 0.001). The incidence of deficiency of PC at day 100 was lower in patients undergoing peripheral stem cell transplantation compared with patients undergoing autologous BMT (12.5{\%} vs 35{\%}; P = 0.05), although several significant confounding variables exist. We conclude that deficiencies in protein C persist at least 100 days after stem cell transplantation in nearly one quarter of patients undergoing this procedure. Therefore, patients undergoing stem cell transplantation may be at prolonged risk of thrombotic and other complications. Further studies to determine the risk of prolonged deficiency based on stem cell source need to be performed.",
keywords = "Hematopoietic growth factors, Hypercoagulable state, Protein C",
author = "Gordon, {Bruce Geoffrey} and W. Haire and E. Ruby and L. Stephens and G. Kotulak and A. Kessinger",
year = "1996",
month = "3",
day = "1",
language = "English (US)",
volume = "17",
pages = "415--419",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Prolonged deficiency of protein C following hematopoietic stem cell transplantation

AU - Gordon, Bruce Geoffrey

AU - Haire, W.

AU - Ruby, E.

AU - Stephens, L.

AU - Kotulak, G.

AU - Kessinger, A.

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Deficiencies in circulating anticoagulant protein C (PC) occur in patients undergoing hematopoietic stem cell transplantation. These deficiencies may predispose to thrombotic and other complications, and may contribute to the morbidity of transplantation. In most patients, PC reaches a nadir 14 days after the preparative regimen and then begins to increase toward normal. However, low PC has been seen months after transplantation. Neither the frequency of, nor risk factors for, this prolonged deficiency are known. We examined 71 adults undergoing stem cell transplantation and found low PC antigen and activity in 21% and 20% of patients, respectively. Low PC at day 100 correlated strongly with low PC pre-chemotherapy (PC antigen, r = 0.69, P < 0.001; PC activity, r = 0.59, P < 0.001). The incidence of deficiency of PC at day 100 was lower in patients undergoing peripheral stem cell transplantation compared with patients undergoing autologous BMT (12.5% vs 35%; P = 0.05), although several significant confounding variables exist. We conclude that deficiencies in protein C persist at least 100 days after stem cell transplantation in nearly one quarter of patients undergoing this procedure. Therefore, patients undergoing stem cell transplantation may be at prolonged risk of thrombotic and other complications. Further studies to determine the risk of prolonged deficiency based on stem cell source need to be performed.

AB - Deficiencies in circulating anticoagulant protein C (PC) occur in patients undergoing hematopoietic stem cell transplantation. These deficiencies may predispose to thrombotic and other complications, and may contribute to the morbidity of transplantation. In most patients, PC reaches a nadir 14 days after the preparative regimen and then begins to increase toward normal. However, low PC has been seen months after transplantation. Neither the frequency of, nor risk factors for, this prolonged deficiency are known. We examined 71 adults undergoing stem cell transplantation and found low PC antigen and activity in 21% and 20% of patients, respectively. Low PC at day 100 correlated strongly with low PC pre-chemotherapy (PC antigen, r = 0.69, P < 0.001; PC activity, r = 0.59, P < 0.001). The incidence of deficiency of PC at day 100 was lower in patients undergoing peripheral stem cell transplantation compared with patients undergoing autologous BMT (12.5% vs 35%; P = 0.05), although several significant confounding variables exist. We conclude that deficiencies in protein C persist at least 100 days after stem cell transplantation in nearly one quarter of patients undergoing this procedure. Therefore, patients undergoing stem cell transplantation may be at prolonged risk of thrombotic and other complications. Further studies to determine the risk of prolonged deficiency based on stem cell source need to be performed.

KW - Hematopoietic growth factors

KW - Hypercoagulable state

KW - Protein C

UR - http://www.scopus.com/inward/record.url?scp=0029865507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029865507&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 415

EP - 419

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -